Morgan L Swank1, Deborah A Wing2, David P Nicolau3, Jennifer A McNulty4. 1. Department of Obstetrics & Gynecology, University of California, Irvine, Medical Center, Orange, CA; Miller Children's and Women's Hospital, Long Beach Memorial, Long Beach, CA. Electronic address: mswank@uci.edu. 2. Department of Obstetrics & Gynecology, University of California, Irvine, Medical Center, Orange, CA. 3. Center for Anti-Infective Research and Development, Hartford Hospital, Hartford, CT. 4. Miller Children's and Women's Hospital, Long Beach Memorial, Long Beach, CA.
Abstract
OBJECTIVE: The purpose of this study was to determine tissue concentrations of cefazolin after the administration of a 3-g prophylactic dose for cesarean delivery in obese women (body mass index [BMI] >30 kg/m(2)) and to compare these data with data for historic control subjects who received 2-g doses. Acceptable coverage was defined as the ability to reach the minimal inhibitory concentration (MIC) of 8 μg/mL for cefazolin. STUDY DESIGN: We conducted a 2-phase investigation. The current phase is a prospective cohort study of the effects of obesity on tissue concentrations after prophylactic 3-g cefazolin doses at the time of cesarean delivery. Concentration data after 3-g were compared with data for historic control subjects who had received 2-g. Three grams of parenteral cefazolin was given 30-60 minutes before skin incision. Adipose samples were collected at both skin incision and closure. Cefazolin concentrations were determined with the use of a validated high-performance liquid chromatography assay. RESULTS: Twenty-eight obese women were enrolled in the current study; 29 women were enrolled in the historic cohort. BMI had a proportionally inverse relationship on antibiotic concentrations. An increase of the cefazolin dose dampened this effect and improved the probability of reaching the recommended MIC of ≥8 μg/mL. Subjects with a BMI of 30-40 kg/m(2) had a median concentration of 6.5 μg/g (interquartile range [IQR], 4.18-7.18) after receiving 2-g vs 22.4 μg/g (IQR, 20.29-34.36) after receiving 3-g. Women with a BMI of >40 kg/m(2) had a median concentration of 4.7 μg/g (IQR, 3.11-4.97) and 9.6 μg/g (IQR, 7.62-15.82) after receiving 2- and 3-g, respectively. With 2 g of cefazolin, only 20% of the cohort with a BMI of 30-40 kg/m(2) and none of the cohort with a BMI of >40 kg/m(2) reached an MIC of ≥8 μg/mL. With 3-g, all women with a BMI of 30-40 kg/m(2) reached target MIC values; 71% of the women with a BMI of >40 kg/m(2) attained this cutoff. CONCLUSION: Higher adipose concentrations of cefazolin were observed after the administration of an increased prophylactic dose. This concentration-based pharmacology study supports the use of 3 g of cefazolin at the time of cesarean delivery in obese women. Normal and overweight women (BMI <30 kg/m(2)) reach adequate cefazolin concentrations with the standard 2-g dosing.
OBJECTIVE: The purpose of this study was to determine tissue concentrations of cefazolin after the administration of a 3-g prophylactic dose for cesarean delivery in obesewomen (body mass index [BMI] >30 kg/m(2)) and to compare these data with data for historic control subjects who received 2-g doses. Acceptable coverage was defined as the ability to reach the minimal inhibitory concentration (MIC) of 8 μg/mL for cefazolin. STUDY DESIGN: We conducted a 2-phase investigation. The current phase is a prospective cohort study of the effects of obesity on tissue concentrations after prophylactic 3-g cefazolin doses at the time of cesarean delivery. Concentration data after 3-g were compared with data for historic control subjects who had received 2-g. Three grams of parenteral cefazolin was given 30-60 minutes before skin incision. Adipose samples were collected at both skin incision and closure. Cefazolin concentrations were determined with the use of a validated high-performance liquid chromatography assay. RESULTS: Twenty-eight obesewomen were enrolled in the current study; 29 women were enrolled in the historic cohort. BMI had a proportionally inverse relationship on antibiotic concentrations. An increase of the cefazolin dose dampened this effect and improved the probability of reaching the recommended MIC of ≥8 μg/mL. Subjects with a BMI of 30-40 kg/m(2) had a median concentration of 6.5 μg/g (interquartile range [IQR], 4.18-7.18) after receiving 2-g vs 22.4 μg/g (IQR, 20.29-34.36) after receiving 3-g. Women with a BMI of >40 kg/m(2) had a median concentration of 4.7 μg/g (IQR, 3.11-4.97) and 9.6 μg/g (IQR, 7.62-15.82) after receiving 2- and 3-g, respectively. With 2 g of cefazolin, only 20% of the cohort with a BMI of 30-40 kg/m(2) and none of the cohort with a BMI of >40 kg/m(2) reached an MIC of ≥8 μg/mL. With 3-g, all women with a BMI of 30-40 kg/m(2) reached target MIC values; 71% of the women with a BMI of >40 kg/m(2) attained this cutoff. CONCLUSION: Higher adipose concentrations of cefazolin were observed after the administration of an increased prophylactic dose. This concentration-based pharmacology study supports the use of 3 g of cefazolin at the time of cesarean delivery in obesewomen. Normal and overweight women (BMI <30 kg/m(2)) reach adequate cefazolin concentrations with the standard 2-g dosing.
Authors: William J Peppard; David G Eberle; Nathan W Kugler; Danielle M Mabrey; John A Weigelt Journal: Surg Infect (Larchmt) Date: 2016-12-01 Impact factor: 2.150
Authors: Eliza C Miller; Marisa Gallo; Erin R Kulick; Alexander M Friedman; Mitchell S V Elkind; Amelia K Boehme Journal: Stroke Date: 2018-05 Impact factor: 7.914
Authors: Kim A Boggess; Alan Tita; Victoria Jauk; George Saade; Sherri Longo; Erin A S Clark; Sean Esplin; Kristin Cleary; Ronald Wapner; Kelli Letson; Michelle Owens; Sean Blackwell; Carmen Beamon; Jeffrey M Szychowski; William Andrews Journal: Obstet Gynecol Date: 2017-03 Impact factor: 7.661
Authors: Hanadi H Alrammaal; Khaled Abduljalil; Victoria Hodgetts Morton; R Katie Morris; John F Marriott; Hsu P Chong; Hannah K Batchelor Journal: Pharmaceutics Date: 2022-05-30 Impact factor: 6.525
Authors: Amy M Valent; Chris DeArmond; Judy M Houston; Srinidhi Reddy; Heather R Masters; Alison Gold; Michael Boldt; Emily DeFranco; Arthur T Evans; Carri R Warshak Journal: JAMA Date: 2017-09-19 Impact factor: 56.272
Authors: Kevin R Theis; Roberto Romero; Andrew D Winters; Jonathan M Greenberg; Nardhy Gomez-Lopez; Ali Alhousseini; Janine Bieda; Eli Maymon; Percy Pacora; Jennifer M Fettweis; Gregory A Buck; Kimberly K Jefferson; Jerome F Strauss; Offer Erez; Sonia S Hassan Journal: Am J Obstet Gynecol Date: 2019-03 Impact factor: 10.693